Pulses of Hope: How Electric Energy Is Opening a New Path in Advanced Lung Cancer

In the world of oncology, few battles are as challenging as the one against stage IV lung cancer. Even with advances in immunotherapy and targeted treatments, many patients face limited survival due to tumor resistance, unstoppable disease progression, or accumulated toxicity from systemic therapies.

But now, a new approach is electrifying the field: pulsed electric field ablation (PEF). Far from science fiction, this technique combines technological precision with the power of the immune system and may mark the beginning of a new era for patients who have run out of options.

An interdisciplinary team led by Dr. William H. Moore and composed of experts from NYU Grossman School of Medicine, Weill Cornell Medicine, and Duke Health, has shared its early experience using this technique in patients with stage IV non-small cell lung cancer (NSCLC) who had already failed multiple lines of treatment. The study, published in Lung Cancer, offers striking results that deserve attention.

What Exactly Is PEF?

Pulsed electric field ablation consists of the controlled application of high-intensity, short-duration electric pulses to the tumor tissue. This is done using a needle or probe inserted directly into the tumor under image guidance (CT or ultrasound). These pulses generate irreversible electroporation, creating small pores in the cell membranes, destabilizing them until they induce cell death without heat.

Unlike conventional thermal ablations (such as radiofrequency or microwave), PEF preserves the connective tissue architecture and avoids massive destruction of the surrounding tumor environment. This is crucial because it keeps open the “pathways” for immune cells to infiltrate and access the tumor.

In addition to destroying tumor cells through apoptosis and controlled necrosis, PEF provokes the release of danger signals (DAMPs) that activate the immune system. Preclinical models had already shown that this type of cell death can promote the arrival of cytotoxic T cells, M1 macrophages, and the formation of tertiary lymphoid structures (TLS)—small immune command centers near the tumor, highly associated with better immunotherapy responses.

What Did the Researchers Do?

In this multicenter retrospective study, 41 patients with stage IV lung cancer who were treated with PEF between January 2023 and July 2024 were analyzed. All of them had received at least one line of systemic treatment (immunotherapy, chemotherapy, or both) without clinical benefit.

As a comparison, a group of 50 similar patients treated only with conventional systemic therapy was included. The comparison was matched by age, stage, tumor burden, comorbidities, and previous treatments.

Tumor response was assessed using RECIST 1.1 criteria, while progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier curves and hazard ratio analysis.

What Did They Find?

The results were impressive, especially considering that these were patients selected for their treatment resistance:

1-year PFS:

63.2% in the PEF-treated group

11.8% in the control group

1-year OS:

74.3% in the PEF group

33% in the control group

Even within the PEF group, patients whose ablation covered more than 60% of the tumor volume showed better clinical outcomes, with a median survival extended by over 100 days compared to those with less complete ablations.

Regarding objective response, 75.6% of PEF-treated patients maintained stable disease or achieved partial response. In the control group, that number was only 14%. This suggests that even without a full radiologic response, tumor control is significantly greater with PEF.

The treatment was well tolerated: only five cases of pneumothorax were reported, four of which required chest tube placement. There were no cases of severe hemoptysis, bronchopleural fistulas, or serious procedure-related infections.

Figure 1. PEF induces non-thermal tumor cell death while preserving surrounding tissue, promoting immune infiltration and formation of tertiary lymphoid structures (TLS). Compared to standard treatment, PEF significantly improves survival outcomes in refractory stage IV NSCLC patients.

What Does This Mean for the Future of Treatment?

Although the authors are cautious in acknowledging that this is a retrospective and limited study, the findings open a hopeful door. PEF’s ability to not only destroy the tumor locally, but also activate the immune system, raises the possibility of using it as an immunotherapy enhancer or even as a first-line combination treatment.

It also suggests we may be entering a new generation of locoregional therapies, where the goal is not just to reduce tumor mass but to convert “cold” (immunologically inert) tumors into “hot” (immune-active) ones. This is key to expanding the reach of immunotherapy to more tumor types and more patients.

Conclusion

This work led by Dr. Moore and colleagues demonstrates that a simple needle emitting electricity can have a transformative effect, not only on the tumor but on the relationship between cancer and the immune system.

Pulsed electric field ablation (PEF) emerges as a local, safe, well-tolerated, and potentially immunomodulatory intervention, especially useful in patients with no therapeutic alternatives. And although we are still in an early phase of evidence, its initial effectiveness suggests we may be facing a new tool in the fight against advanced lung cancer, and potentially against other types of solid tumors.

As often happens with major breakthroughs, it all started with a spark. And this time—literally.

Main Reference:

Moore, W. H., Silk, M., Bhattacharji, P., Pua, B. B., Mammarappallil, J., Sterman, D. H., & Chachoua, A. (2025). Early experience with PEF in the setting of recalcitrant stage IV lung cancer. Lung cancer (Amsterdam, Netherlands), 204, 108575. Advance online publication. https://doi.org/10.1016/j.lungcan.2025.108575

Other References:

Russano, M., La Cava, G., Cortellini, A., Citarella, F., Galletti, A., Di Fazio, G. R., Santo, V., Brunetti, L., Vendittelli, A., Fioroni, I., Pantano, F., Tonini, G., & Vincenzi, B. (2023). Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. Current Oncology, 30(2), 2366-2387. https://doi.org/10.3390/curroncol30020181

Padinharayil, H., Alappat, R. R., Joy, L. M., Anilkumar, K. V., Wilson, C. M., George, A., Valsala Gopalakrishnan, A., Madhyastha, H., Ramesh, T., Sathiyamoorthi, E., Lee, J., & Ganesan, R. (2022). Advances in the Lung Cancer Immunotherapy Approaches. Vaccines, 10(11), 1963. https://doi.org/10.3390/vaccines10111963

Bratova, M., Skrickova, J., Matusikova, M. et al. Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer. J Cancer Res Clin Oncol 149, 17123–17131 (2023). https://doi.org/10.1007/s00432-023-05431-5